Lucent Diagnostics Announces Collaboration with Tempus to Integrate Blood-Based Alzheimer’s Biomarker Testing into Clinical Workflows
Go back to Lucent Diagnostics Announces Collaboration with Tempus to Integrate Blood-Based Alzheimer’s Biomarker Testing into Clinical Workflows| (NASDAQ: QTRX) | Delayed: 3.47 +0.08 (2.36%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.39 | 52 Week High | $ | |||
| Open | $3.40 | 52 Week Low | $ | |||
| Day High | $3.54 | P/E | N/A | |||
| Day Low | $3.18 | EPS | $ | |||
| Volume | 1,062,658 | |||||
| StemCells, Inc. (NASDAQ: TEM) | Delayed: 47.97 -2.87 (5.65%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $50.84 | 52 Week High | $0.45 | |||
| Open | $49.75 | 52 Week Low | $0.37 | |||
| Day High | $51.27 | P/E | N/A | |||
| Day Low | $47.64 | EPS | $-0.31 | |||
| Volume | 4,028,204 | |||||

